How do you manage new-onset vitiligo in a patient on immune checkpoint inhibitors?

Vitiligo is quite often (not always) associated with good long-term clinical outcomes for melanoma patients treated with immune checkpoint therapy. It is an indication of the activity of the drug, as it is due to unleashing of the T-cells’ attack on the bystander melanocytes in addition to melanoma ...

I refer to dermatology. There is really not much that can be done. Vitiligo usually stays and may resolve very slowly. The patient needs extensive education on sun protection. The decision to continue depends on the risk-benefit ratio and the discussion with the patient. For example, if this is a lo...

I refer to dermatology when the vitiligo is extensive, causes discomfort due to the site of involvement (face), or is associated with significant pruritus. It is worth noting that topical ruxolitinib was recently FDA-approved for vitiligo treatment. Rosmarin et al., PMID 36260792

The utility (efficac...